Cantor Fitzgerald analyst Varun Kumar last night initiated coverage of Compugen with an Overweight rating and $10 price target. The analyst is "cautiously positive" on the Compugen story and sees it as a high-risk/high-reward play in the next 12-18 months. A large biopharma company may be willing to form a more matured and strategic partnership around COM701 asset post the second half of 2020 combo/first half of 2021 single-agent data if results support PVRIG as a potential first-in-class immuno-oncology agent, Kumar tells investors in a research note.